Latest Interviews
Showing 16–30 of 41 transcripts.
Clear all filters- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.
- a16z27 min
a16z Podcast | Shifting Risk Mindsets, From Tech to Bio
Vijay Pande, Jorge Conde, Jeff Low, Jeffrey Lowe
This event guides tech founders through the critical challenges of translating their innovations into the biotechnology sector, emphasizing the necessity of treating biotech firms as data-driven enterprises. It details strategies to avoid operational pitfalls like "death by a thousand pilots" and outlines structural frameworks, such as LLC ring-fencing, to protect platform value while developing proprietary assets. Furthermore, the session provides actionable insights on diagnostics reimbursement, early validation "kill tests," and aligning hybrid investor syndicates to ensure sustainable growth in a high-barrier market.
- a16z8 min
a16z Podcast | On Recent Consolidation in the Healthcare Industry
Jorge Conde, Vijay Pande, Jeffrey Low
Major healthcare players are driving industry consolidation through vertical integration strategies exemplified by Walmart's potential Humana acquisition and the Amazon-JP Morgan-Berkshire consortium. These moves aim to collapse the value chain from manufacturers to insurers, though speakers distinguish between locally dominant retailers and geographically dispersed employer groups regarding their pricing power. As Amazon targets opaque PBM margins without acquiring marquee assets, the market anticipates new entrepreneurial opportunities in specialized genomic and cell therapy logistics to manage rising treatment costs.
- a16z22 min
a16z Podcast | When (and How) Biology Becomes Engineering
The event details the transformative shift in biology from a stochastic, discovery-based science to a standardized engineering discipline that treats biological components as predictable, interchangeable parts. Interdisciplinary innovation and machine learning now drive this transition by enabling repeatable design-build-refine cycles that replace traditional high-risk experimentation with data-driven predictability. This engineering mindset aims to commercialize biological platforms through measurable success rates and sustainable infrastructure, ultimately making previously impossible medical and industrial goals achievable through compounding technological improvements.
- a16z29 min
a16z Podcast | Taking the Pulse on Bio
Jorge Conde, Vijay Pande, Malinka Walaliyadde, Jeffrey Low, Hannah
A16Z is shifting its bio-investment thesis from empirical science to engineered biology, prioritizing ventures where established biological mechanisms allow founders to apply AI and data-driven engineering to de-risk development. This approach targets sectors like diagnostic genomics and cell therapies, leveraging network effects and reusable platforms to transform unpredictable research into scalable, schedulable manufacturing processes. By favoring hybrid founders with expertise in both computer science and biology, the firm aims to accelerate innovation cycles and capture value in an era where technical execution supersedes novel biological discovery.
- a16z30 min
a16z Podcast | Putting AI in Medicine, in Practice
Brandon Ballinger, Mintu Turakhia, Vijay Pande, Hanne Tidnam, Hannah
This analysis outlines the evolution of AI in healthcare from early expert systems to modern deployment strategies driven by shifting "fee-for-value" reimbursement models that reward accurate diagnosis. It details technical approaches where algorithms substitute tasks in radiology or complement physicians by processing dense data streams, while navigating critical challenges in model generalization, liability frameworks, and regulatory compliance. Commercial adoption is projected to accelerate through full-stack startups selling directly to employers, ultimately reshaping the industry from reactive, geographic models to proactive, data-centric vertical networks.
- a16z29 min
a16z Podcast | Mindsets for Engineering Biology
Bob Langer, Vijay Pande, Hanne Tidnam, Hannah
This presentation traces the evolution of biomaterials and drug delivery from 20th-century improvisation to modern rational engineering driven by high-throughput automation and robotics. It details how regulatory shifts and the transition to protein and gene therapies have necessitated sophisticated controlled-release systems for treating complex diseases like cancer and diabetes. Looking forward, the industry is pivoting toward regenerative medicine and longevity research, aiming to solve critical challenges in organ engineering and multi-omics data interpretation.
- a16z27 min
a16z Podcast | The Taxonomy of Collective Knowledge
Luis von Ahn, Jay Komarneni, Vijay Pande, Malinka Walaliyadde
This presentation explores the evolution of data ontologies as structured frameworks that enable scalable coordination between human cognition and machine processing. It details specific implementations such as reCAPTCHA, Duolingo, and HumanDx, which leverage collective intelligence to solve complex tasks ranging from text recognition to medical diagnosis. By integrating weighted human expertise with algorithmic efficiency, the discussion outlines a future trajectory where these hybrid systems democratize access to high-level knowledge and healthcare without replacing individual professionals.
- a16z25 min
a16z Podcast | The Cloud Atlas to Real Quantum Computing
Jeff Cordova, Vijay Pande, Sonal Chokshi
Transitioning from theoretical research to an engineering phase, the quantum computing industry currently utilizes software simulators and cloud-based hybrid architectures to bridge the gap between fragile, cryogenically cooled hardware and classical data processing. Major technology firms and agile startups are concurrently developing specialized algorithms for computational chemistry and machine learning, leveraging the hyper-exponential scaling of qubit counts to achieve a sudden dominance over classical systems. While early applications focus on simulating molecular interactions, the market anticipates a rapid shift where specialized quantum microservices will allow developers to access these transformative capabilities without managing the underlying physical infrastructure.
- a16z35 min
a16z Podcast | What Technology Wants, Needs, Does
Marc Andreessen, Frank Chen, Vijay Pande, Alex Rampell
This panel examined critical regulatory tensions in healthcare and fintech, analyzing how the shift to pay-for-value models and Dodd-Frank risk retention rules create new barriers for startups while enabling regulatory arbitrage. Experts further debated the ethical implications of AI in lending and medicine, highlighting the conflict between opaque deep learning algorithms and existing fair-lending laws alongside the potential for technology to render physical travel obsolete through high-fidelity telepresence. The discussion concluded by projecting how innovations in genomic risk scoring, autonomous logistics, and lab-grown organs will fundamentally reshape social determinants of health and long-term human longevity.
- a16z26 min
a16z Podcast | The Rise of the Digital 'Pill'
Sean Duffy, Vijay Pande, Malinka Walaliyadde, Hannah, Malinka Walaliate
Digital health has evolved into a distinct third wave of therapeutics that treats behavioral and metabolic conditions through software-driven clinical interventions validated by rigorous randomized controlled trials. Despite past skepticism from medical authorities, industry leaders are overcoming adoption barriers by demonstrating superior efficacy in areas like diabetes management and shifting payment models toward value-based outcomes. The sector is increasingly integrating with existing healthcare infrastructure to act as a clinical collaborator rather than a replacement, with artificial intelligence poised to deepen this impact while addressing global provider shortages.
- a16z29 min
a16z Podcast | The Science Of Extending Life
Dr. Thomas Rando, Kristen Fortney, Vijay Pande, Hannah
Geroscience has transitioned from theoretical concepts to validated interventions like rapamycin and senolytics, which extend lifespan by up to 30% in mammalian models while genomic biomarkers accelerate drug testing from decades to years. Regulatory frameworks are evolving to approve age-delaying therapies such as the FDA's review of the TAME metformin trial, shifting focus from treating specific diseases to preventing aging as a primary risk factor. BioAge and other entities are developing diverse therapeutics to add healthy years to life, aiming to generate massive public cost savings and reshape demographics despite challenges regarding equity and access.
- a16z17 min
a16z Podcast | The Business of Healthcare
Rajeev Singh, Vijay Pande, Sean Duffy
Driven by a projected rise in healthcare spending to 19% of GDP and a critical Type 2 diabetes epidemic, the industry is pivoting toward value-based care models led by firms like Omada and Accolade. These companies differentiate themselves through a hybrid tech-persona approach that pairs digital tools with human coaching, securing competitive moats via longitudinal clinical data rather than traditional patent protections. By rejecting fee-for-service structures in favor of outcomes-based pricing and navigating complex regulatory environments, these organizations aim to establish chronic disease management as a mandatory standard of care for a significant portion of the U.S. population within the next five years.
- a16z14 min
a16z Podcast | The Genetics Of Drug Delivery
Stanford professor Russ Altman leads a data science laboratory that integrates molecular, cellular, and population-level data to optimize drug response and identify previously unknown side effects. By analyzing diverse sources ranging from electronic medical records to web search logs, Altman's team successfully uncovered critical interactions, such as a glucose spike caused by combining paroxetine and pravastatin, and predicted new therapeutic uses for existing cancer drugs. This multi-scale approach, supported by funding from the National Institutes of Health and industry partners like Pfizer and Genentech, aims to replace fragmented clinical trial models with continuous, data-driven surveillance for safer and more effective pharmaceutical development.
- a16z30 min
a16z Podcast | Health Data -- A Feedback Loop for Humanity
Jeffrey Kaditz, Vijay Pande, Sonal Chokshi, Jeff Kaditz
Jeff Kaditz and Q.bio advocate replacing the current reactive medical model with a longitudinal physiology tracking system that establishes personalized baselines to predict disease before symptoms emerge. By treating the human body as a dynamic time-series rather than a static snapshot, the initiative aims to reduce false positives and align healthcare with the proven preventative success of modern dentistry. This shift requires overcoming economic barriers in fee-for-service reimbursement and establishing a framework for patient data ownership to create a predictive feedback loop that could eventually eliminate deaths from treatable conditions.